In addition, side effects of the posterior segment, such as RVO (18), ME, and central serous retinopathy, have been reported with systemic anti-VEGF agents (30), which are consistent with the results of animal experiments showing decreased local blood flow secondary to retinal vascular endothelial cell dysfunction with systemic anti-VEGF treatment (31). This evidence concerns the gene VEGFA and central serous retinopathy.